Human medicines European public assessment report (EPAR): Enhertu, trastuzumab deruxtecan, Breast Neoplasms, Date of authorisation: 18/01/2021, Status: Authorised

SEMrush
Human medicines European public assessment report (EPAR): Enhertu, trastuzumab deruxtecan, Breast Neoplasms, Date of authorisation: 18/01/2021, Status: Authorised
[automaticbacklinks]